Compare CNK & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | RLAY |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.1B |
| IPO Year | 2007 | 2020 |
| Metric | CNK | RLAY |
|---|---|---|
| Price | $35.87 | $18.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $33.70 | $19.50 |
| AVG Volume (30 Days) | ★ 2.6M | 2.6M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,115,000,000.00 | $15,355,000.00 |
| Revenue This Year | $11.01 | N/A |
| Revenue Next Year | $3.70 | $324.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.15 | ★ 53.44 |
| 52 Week Low | $21.60 | $3.03 |
| 52 Week High | $37.50 | $20.79 |
| Indicator | CNK | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 74.61 | 50.65 |
| Support Level | $22.03 | $18.33 |
| Resistance Level | N/A | $20.59 |
| Average True Range (ATR) | 1.24 | 1.08 |
| MACD | 0.57 | -0.24 |
| Stochastic Oscillator | 84.22 | 29.48 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres. Cinemark manages its business under two reportable segments: U.S. markets and international markets. The majority of its revenue is generated from the U.S. markets segment.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.